Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.

Inclusion Criteria

• •Males or females.
• •Diagnosed with breast cancer, as defined by the International Classification of Diseases (ICD), 9th or 10th Revision, Clinical Modification (ICD-9-CM 174.xx, 175.xx/ICD-10-CMC50.xx).
• •Aged ≥18 years (or local legal age of consent) at the date of initial breast cancer diagnosis.
• •Patients with anatomic staging II and III as determined using American Joint Committee on Cancer (AJCC) Criteria.
• •Have initiated adjuvant therapy with ribociclib or abemaciclib, per the approved local label, in combination with ET (within 14 days prior to enrollment).
• •Have HR+ status, as determined by the closest biomarker test on or before the adjuvant therapy initiation date:
• •* Tested positive for estrogen receptor (ER+), or
• •* Tested positive for progesterone receptor (PR+), or
• •* Tested positive for both.
• •Tested negative for HER2 (HER2-) using the closest biomarker test on or before the adjuvant therapy initiation date.